The new ITMN-191 trial you cited is bearish for the ritonavir-boosted ITMN-191 program, IMO. Rather than progressing to a phase-2b study that measures SVR, Roche is evidently running another small PK/safety study.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.